Explore the implementation of PUPSIT and the infrastructure, processes and expertise needed to support sterile filtration compliance under EU GMP Annex 1.

The revised EU GMP Annex 1 has reinforced the expectation that contamination control and sterility assurance should be embedded throughout sterile manufacturing, rather than assessed primarily through end-of-process checks. Among its most discussed requirements is pre-use post-sterilisation integrity testing (PUPSIT) of sterilising-grade filters.
For manufacturers supplying Europe, PUPSIT is generally regarded by regulators as a standard component of a compliant sterile filtration strategy – not an optional addition. Sponsors pursuing EU approval, including those considering future European expansion, must therefore account for it alongside isolator technology, comprehensive environmental monitoring and a formal contamination control strategy.
Successful implementation, however, requires more than installing a test instrument. Facility infrastructure, filtration assemblies, validated methods and operator expertise must work together to make testing reliable and repeatable.
Understanding the risk PUPSIT addresses
A sterilising filter can sustain damage during transportation, handling, assembly or sterilisation, yet subsequently pass a post-use integrity test. This can happen when product fouling partially masks a defect during filtration. By reducing flow through the compromised membrane, the product can allow a damaged filter to meet the post-use acceptance limits.
PUPSIT addresses this possibility by checking filter integrity after sterilisation and immediately before sterile filtration begins.
To perform the test, operators wet the filter with an appropriate medium – typically water, buffer or product. The choice depends on the filter design, supporting validation data and product characteristics. A connected instrument then performs an automated integrity test using validated parameters, including pressure, hold time and acceptance limits.
This produces a quantitative result and a pass/fail determination before product filtration. The timing matters: demonstrating that the filter is integral when it is needed provides a stronger control than relying solely on a test conducted after the batch has passed through it.
Regulatory expectations and justified alternatives
Annex 1 states that “the integrity of sterilized filter assembly should be verified by integrity testing before use (PUPSIT).” In regulatory practice, this establishes the default expectation. The US FDA, by comparison, has not made PUPSIT mandatory, leaving global programmes to accommodate different regional expectations within their filtration strategies.
For EU-bound products, a decision to omit PUPSIT needs a robust, documented risk assessment demonstrating that the likelihood of damage being masked is acceptably low.”
For EU-bound products, a decision to omit PUPSIT needs a robust, documented risk assessment demonstrating that the likelihood of damage being masked is acceptably low. Relevant considerations typically include the following:
- Filter type, manufacturer and manufacturing method
- Transportation, storage and sterilisation arrangements
- Packaging, handling and inspection procedures
- Product characteristics – particularly the potential to foul membranes or conceal defects.
Very small batches can present particular difficulties. Filter wetting and testing may consume a substantial proportion of the available volume, making implementation technically or economically challenging.
An alternative approach may be justified in these circumstances, but sponsors should anticipate extensive supporting data and close engagement with the qualified person (QP) and regulators. For many commercial programmes, the work and uncertainty involved in justifying omission exceed the effort required to incorporate PUPSIT from the beginning.
Where implementation becomes challenging
Two concerns frequently shape discussions about PUPSIT. First, additional valves, connections and manipulations may introduce risks into an otherwise closed sterile system. Second, testing may increase costs and delay batch release compared with a post-use-only approach.
Integrity testing itself is not intrinsically complex. The challenge lies in performing it in situ on production equipment while maintaining control of the sterile pathway.”
These concerns warrant attention, but the distinction between the test and its execution is important. Integrity testing itself is not intrinsically complex. The challenge lies in performing it in situ on production equipment while maintaining control of the sterile pathway.
Extra connection points, manual interventions and the need for complete, consistent filter wetting introduce failure modes that are less prominent in offline testing. Many observed failures relate to technique rather than defective filters or instruments: inadequate wetting, trapped air, inconsistent methods and limited understanding of fluid dynamics can all contribute.
Addressing these issues requires deliberate system design, practical training and operational experience.
Making PUPSIT a facility design requirement
Integrating PUPSIT into the initial design of a sterile fill/finish facility allows equipment layouts, utilities and automation to support testing without unnecessary contamination risks or operational complications. Retrofitting the same capability into an established layout can be considerably less straightforward.
A purpose-built, large-scale isolator-based facility can incorporate the following:
- Isolators suited to commercial throughput and flexible vial formats, reducing operator intervention in the critical zone
- Defined utility and piping routes, including connections for integrity testing equipment
- Walkable ceilings and external maintenance access, limiting interventions within classified areas throughout the facility lifecycle
- Redundant clean utilities and equipment, supporting maintenance and unexpected downtime without compromising ongoing sterility assurance activities.
These features support Annex 1’s proactive approach to contamination control while making PUPSIT a routine process step. They also enable high-speed isolated vial filling lines, including those accommodating broad vial-size ranges, to be validated with testing requirements already incorporated.
The objective is not simply to provide space for another instrument, but to ensure the wider manufacturing environment supports its consistent use.
Simplifying execution through modular assemblies
Single-use assembly design has a direct influence on PUPSIT reliability. Standardised, modular sub-assemblies offer an alternative to maintaining numerous bespoke, all-in-one configurations.
Standardised, modular sub-assemblies offer an alternative to maintaining numerous bespoke, all-in-one configurations.”
Within a modular system, tubing sizes, pre-filters, sterilising filters, flush bags and integrity test connections can be selected and combined for individual products and processing requirements. Changes do not necessarily require a complete assembly redesign, and a problematic component can be replaced without discarding the full build.
The same core components can also serve multiple clients, providing several practical benefits:
- Greater flexibility when processes change or increase in scale
- Shorter lead times through fewer unique part numbers requiring qualification and stocking
- More consistent execution as operators become familiar with a smaller set of standardised building blocks.
PUPSIT requirements can be incorporated directly into these modules. Appropriately located test ports, pre-filtration options that help mitigate air locking during wetting and effective drainage routes for flushing wetting media can improve test success rates while reducing the burden of aseptic manipulation.
Turning procedures into consistent practice
Even well-designed facilities and assemblies depend on competent execution. Incomplete wetting, inadequate venting of entrapped air or incorrect interpretation of test results can undermine the control PUPSIT is intended to provide.
Teams performing PUPSIT regularly across different molecules and assembly configurations accumulate practical knowledge that can be harder to develop in lower-throughput settings. Experienced operators can recognise filters that are difficult to wet and identify when additional measures are appropriate.
These may include pre-filtering the wetting agent to reduce air locking, maintaining sufficient system back pressure during wetting or adjusting flush volumes. Applying such measures appropriately helps reduce false failures, distinguish technique-related problems from genuine filter issues, and protect batch integrity and manufacturing schedules.
Sponsors assessing a manufacturing partner should therefore look beyond instrument availability and written procedures. Relevant questions include:
- How extensive is operator training?
- How frequently is PUPSIT performed, and across what range of processes?
- How are deviations investigated?
- How are findings translated into improvements in assembly and process design?
Together, these factors provide a more meaningful picture of operational capability than equipment specifications alone.
Planning for a global product lifecycle
For sponsors initially focused on the US, introducing PUPSIT early may appear less urgent than meeting immediate development requirements. However, postponing implementation can create complications when European expansion, scaleup or regional technology transfer becomes necessary.
Early integration can instead support a harmonised filtration strategy that meets EU expectations while remaining acceptable in other markets.”
Adding testing to a mature process may require different assemblies, revised process validation and further regulatory discussions. Early integration can instead support a harmonised filtration strategy that meets EU expectations while remaining acceptable in other markets.
It also reduces the potential need for later revalidation and change control as geographical ambitions expand. Generating data earlier creates opportunities to understand the relationship between PUPSIT performance, filter robustness and product quality outcomes.
Manufacturing location adds another strategic dimension. Renewed interest in domestic North American production, changing trade policies and concerns about supply chain resilience are influencing commercial capacity decisions. Large US facilities combining Annex 1-aligned operations, isolator technology and routine PUPSIT capability consequently have a growing role in sponsors’ long-term supply planning.
Considering filtration requirements alongside these broader decisions helps avoid treating regulatory readiness and manufacturing network strategy as separate exercises.
A connected approach to sterility assurance
PUPSIT is most useful when treated as part of a broader quality-by-design approach, rather than an isolated compliance task. Its effectiveness depends on the relationship between four elements:
- Facility design that reduces inherent contamination risks and supports robust isolator-based operations
- Filtration strategies and single-use assemblies that accommodate testing without unnecessary complexity
- Operator training and experience that deliver consistent execution
- Data-led risk assessments and validation that reconcile global regulatory expectations with manufacturing realities.
Developing these elements together can turn PUPSIT from a potentially variable intervention into a predictable, low-risk part of routine batch processing.
The underlying purpose remains straightforward: to confirm that a critical filtration barrier is intact at the point it is required. When supported by appropriate infrastructure, process design and expertise, PUPSIT strengthens confidence in sterile manufacturing rather than adding uncertainty to it.



No comments yet